Merck & Company News - June 2026
Merck Wins FDA Approval for Keytruda-Trodelvy Combo, Cutting Cancer Risk 35%
The FDA approved Merck’s KEYTRUDA in combination with Gilead’s Trodelvy for advanced triple-negative breast cancer (TNBC). This approval applies to adult...
🟢 MRK is trading 3.2% up today on EU approval for Keytruda bladder cancer combo
MRK is trading 3.2% up at $124.40 after winning a key European regulatory approval for its oncology portfolio. • The European Commission cleared the...
Merck Tulisokibart Hits Phase 3 Goal, First-in-Class Success for Ulcerative Colitis
Merck reported positive topline results from the Phase 3 ATLAS-UC induction-only study for tulisokibart. This investigational treatment targets patients with...